Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
The FDA label specifies use for a few weeks as an adjunct to lifestyle changes
WADA Prohibition The World Anti-Doping Agency classification for these peptides: GLP3 likely classified under prohibited substances as a GLP-1 receptor agonist Cagrilintide status as amylin analog may fall under peptide hormone prohibitions Combined formulation would be prohibited under multiple substance categories No Therapeutic Use Exemptions (TUEs) available for either component Detection methods under development for anti-doping testing WADAs position reflects that these remain investigational agents without regulatory approval from health authorities worldwide
Deep, cystic acne is rarely a purging response
dates 11/1/24-10/1/25
